Inversago Pharma

As a specialty therapeutics, clinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of diabetic kidney disease, type 1 and type 2 diabetes, non-alcoholic steatohepatitis, complications of obesity, hypertriglyceridemia, as well as fibrotic indications such as progressive fibrosis – interstitial lung disease, including idiopathic pulmonary fibrosis. The mechanism of action of Inversago’s molecules addresses the safety limits associated to first generation, centrally-acting CB1 blockers, allowing the company to exploit their full medical potential.